FDA Releases Final Risk Evaluation and Mitigation Strategies (REMS) for Extended Release/Long Acting Opioids Including a Prescriber Education Program Read more
FDA Pain REMS Advisory Committee to Include Presentations on Continuing Education in the Health Professions as a Tool for Implementation Read more